Retinitis Pigmentosa Market Report 2026

The retinitis pigmentosa market size has grown strongly in recent years. It will grow from $12.15 billion in 2025 to $13.16 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to improved understanding of genetic retinal disorders, expansion of diagnostic genetic testing, increased patient advocacy and awareness, availability of vitamin-based supportive therapies, growth of ophthalmic research institutions.

The retinitis pigmentosa market size is expected to see strong growth in the next few years. It will grow to $18.31 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing investments in gene therapy pipelines, rising demand for disease-modifying treatments, expansion of personalized medicine approaches, growing integration of assistive vision technologies, increasing focus on early genetic diagnosis. Major trends in the forecast period include increasing focus on gene-based therapies, rising adoption of retinal prosthetic devices, growing use of genetic testing for diagnosis, expansion of supportive vision enhancement solutions, enhanced research into disease-modifying treatments.

The rise in healthcare expenditure is anticipated to drive the growth of the retinitis pigmentosa market in the coming years. Healthcare expenditure represents the total spending on healthcare products and services, including medical treatments, pharmaceuticals, hospital care, and preventive services, reflecting the overall cost of delivering healthcare within a population. The increase in healthcare spending is driven by factors such as the adoption of advanced medical technologies, aging populations, and the growing burden of chronic diseases. In the context of retinitis pigmentosa, healthcare expenditure is directed toward improving diagnostic capabilities, advancing therapeutic development, and providing supportive care to manage progressive vision loss. For example, in April 2025, according to the American Medical Association (AMA), a US-based professional association, healthcare spending in the United States rose by 7.5% in 2023 to reach $4.9 trillion, averaging approximately $14,570 per person, compared with a 4.6% increase in 2022. Therefore, the growth in healthcare expenditure is fueling the expansion of the retinitis pigmentosa market.

Major companies operating in the retinitis pigmentosa market are increasingly prioritizing the development of innovative treatment approaches, such as gene therapy, to offer more effective and targeted solutions for managing and potentially treating this debilitating eye disorder. Gene therapy for retinitis pigmentosa involves delivering functional copies of genes to replace or correct defective genes responsible for the disease. This advanced therapeutic strategy aims to restore normal function in affected retinal photoreceptor cells, thereby slowing or potentially halting disease progression and vision loss. For instance, in April 2024, ViGeneron GmbH, a Germany-based biotechnology company, initiated a Phase Ib clinical trial to assess the safety, tolerability, and efficacy of VG901, a gene therapy candidate for retinitis pigmentosa caused by mutations in the CNGA1 gene. The open-label, single-arm, dose-escalation study evaluates intravitreal administration of VG901 in patients with autosomal recessive retinitis pigmentosa associated with biallelic CNGA1 mutations.

In December 2023, Théa Pharma Inc., a France-based pharmaceutical company, acquired two antisense oligonucleotide (AON) therapy programs, Sepofarsen (LCA10) and Ultevursen (USH2A), from ProQR Therapeutics N.V. for an undisclosed amount. This acquisition reinforces Théa’s strategic focus on rare genetic ophthalmic diseases. ProQR Therapeutics N.V. is a Netherlands-based biotechnology company specializing in the development of therapies for retinitis pigmentosa and related inherited retinal disorders.

Major companies operating in the retinitis pigmentosa market are Johnson And Johnson, Novartis AG, AbbVie Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd, Spark Therapeutics, REGENXBIO Inc., Editas Medicine, IVERIC bio, MeiraGTx Holdings, Gensight Biologics, Second Sight Medical Products, Copernicus Therapeutics Inc., Kiora Pharmaceuticals, 4D Molecular Therapeutics, Acucela Inc., AGTC Applied Genetic Technologies Corporation, ProQR Therapeutics NV, Nanoscope Therapeutics Inc, Beacon Therapeutics Ltd, Horama SA, ViGeneron GmbH.

North America was the largest region in the retinitis pigmentosa market in 2025. The regions covered in the retinitis pigmentosa market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the retinitis pigmentosa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the retinitis pigmentosa market by increasing costs of imported genetic testing kits, advanced diagnostic equipment, retinal prosthetic components, and research-grade therapeutic materials. Research centers and specialty clinics in North America and Europe are most affected due to reliance on imported high-precision technologies, while Asia-Pacific faces higher R&D equipment costs. These tariffs are increasing research expenditures and slowing technology adoption. However, they are also encouraging domestic biotech innovation, regional research collaborations, and local development of genetic diagnostics and assistive vision solutions.

The retinitis pigmentosa market research report is one of a series of new reports that provides retinitis pigmentosa market statistics, including retinitis pigmentosa industry global market size, regional shares, competitors with a retinitis pigmentosa market share, detailed retinitis pigmentosa market segments, market trends and opportunities, and any further data you may need to thrive in the retinitis pigmentosa industry. This retinitis pigmentosa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Retinitis pigmentosa (RP) is a group of inherited disorders characterized by the gradual degeneration of the retina, leading to progressive vision loss. The condition mainly affects photoreceptor cells, including rods and cones, resulting in symptoms such as night blindness and tunnel vision. Over time, RP can progress to severe visual impairment and blindness.

The main types of retinitis pigmentosa include autosomal recessive, autosomal dominant, and X-linked forms. Autosomal recessive retinitis pigmentosa (AR-RP) occurs when an individual inherits two copies of a mutated gene, one from each parent. Treatment options for retinitis pigmentosa include vitamin A supplementation, docosahexaenoic acid (DHA), calcium channel blockers, gene therapy, retinal prosthetic devices, and other approaches, and diagnosis is carried out using electroretinography, visual field testing, genetic testing, and other methods. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, and these treatments are utilized by end users such as hospitals, specialty clinics, home care settings, and others.

The retinitis pigmentosa market consists of revenues earned by entities by providing services such as genetic counseling, low vision therapy, psychological support, and educational support. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinitis pigmentosa market also includes sales of retinal implants, screen readers, telescopic glasses, and adaptive lighting. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.